Dr. Jorge Short Apellániz, Head of Digital at Quirónsalud, one of Europe's leading hospital networks, explains how AI, robotics, and digital platforms can fundamentally reshape how care is delivered. Recorded in Madrid at University Hospital Rey Juan Carlos, this episode explores why the future of healthcare is not about technology alone but about connecting care across the entire patient journey – before, during, and after treatment. Jorge shares practical examples of innovation in action: from an AI tool that frees doctors from typing notes to robotic surgery that shortens recovery times, to a patient app used by nearly 9.4 million people. A trained physician turned digital leader, Jorge makes the case that digitalization is the catalyst for a much-needed cultural change in healthcare.

What if curing a disease took a single treatment instead of a lifetime of pills, and the same technology could help cool the planet? In this episode, Dr. Bradley Ringeisen, Executive Director of the Innovative Genomics Institute (IGI) at UC Berkeley, takes us inside the CRISPR revolution. From the first FDA-approved sickle cell therapy to a custom cure that saved a baby's life in Philadelphia, to rice engineered to emit 60% less methane, Brad reveals how genome editing is reshaping medicine, climate, and food security alike. We dig into the science, the make-or-break "delivery" challenge, and the IGI's "CRISPR Commons" initiative, a bold plan to make genome editing equitably accessible worldwide.

In this episode, Michel Mommejat, President of A.D.A.M. Innovations, shares how genomics and AI are transforming healthcare from reactive treatment to preventative wellcare. Recorded in Tokyo, this conversation explores what your DNA can reveal as a biological blueprint, why Japan serves as the world's laboratory for healthy aging, and how combining genetic data with biomarkers and lifestyle information creates a dynamic, personalized health ecosystem. Michel also discusses the ethical frameworks needed to protect the most sensitive data that exists, the concept of Artificial General Gene Intelligence, and practical applications like pharmacogenomics that are already changing how we think about medication. Tune in for a visionary conversation on the future of health and longevity.

Lara Gervaise and Edoardo Giudice are the co-founders of Virtuosis AI, a start-up pioneering voice biomarker technology. In this episode, they reveal how just 30 seconds of speech can be analyzed to screen for up to 25 health conditions – from Parkinson's and Alzheimer's to depression, anxiety, and cardiometabolic disorders. They share how a chance meeting before generative AI even existed sparked a conviction that voice and AI could transform preventive care at scale. The conversation covers their path from wellness tool to CE-certified medical device, the ethical safeguards behind their workplace integration, what it takes to build health AI in Europe's regulatory environment, and their ultimate vision: a future where monitoring your voice is as routine as tracking your steps, seamlessly embedded into everyday life.

Nils von Dellingshausen is the CEO and co-founder of BetterDoc, a digital platform transforming how patients find the right doctor for their specific conditions. In this episode, he shares how his company uses proprietary data, expert physician panels, and a rigorous matching methodology to cut through misleading healthcare information and connect patients with their custom-fit medical specialists. He discusses the cultural barriers around second opinions, the critical line between AI-assisted information processing and human medical judgment, and his vision for indication-specific care pathways that follow patients throughout their entire healthcare journey. Tune in for an insightful conversation on patient empowerment, data-driven transparency, and the future of healthcare navigation.

What does it take to get a life-changing medicine from regulatory approval to the patient who needs it? Isabell Remus, Global Head of Biosimilars at Sandoz, reveals why being approved and affordable isn't enough – and how the biosimilar industry learned that trust and education must come before market access. With $320 billion in biologic medicines losing patent exclusivity over the next decade, she explores the strategic complexities of launching at the exact moment a patent expires, the role of diversified manufacturing in strengthening supply chain resilience, and why expanding access to essential medications requires both purpose and commercial viability. An eye-opening conversation on making affordable healthcare a reality for millions of patients worldwide.

In this episode, Dr. Kahina Lang, Executive Director and Head of Next Gen Drug Delivery at Merck Group, discusses her pioneering work developing targeted mRNA delivery systems using lipid nanoparticle (LNP) technology. She shares insights on building an internal startup within the world’s oldest pharmaceutical corporation, the technical innovations enabling precision medicine, and the future of cell and gene therapies. Tune in for an insightful conversation on how entrepreneurial leadership, digital-first research approaches, and open-innovation models are accelerating breakthrough therapeutics from the lab to the clinic.

Professor Masayuki Hirata, founder of JiMED and neurosurgeon at Osaka University, explores how brain-computer interfaces are revolutionizing healthcare for people with disability. From helping ALS patients communicate to controlling avatars and restoring motor function, discover the technology uncoding brain signals.

Recorded live at the Strategy& Future of Health Forum, this special episode features Lucy Jones, Chief Clinical Officer at Oviva, on AI-powered nutrition support for chronic disease management, and Dr. Ashton Harper, Global Medical Affairs Lead for Neurosciences at Roche Diagnostics, on breakthrough blood-based biomarkers revolutionizing Alzheimer's diagnosis. Discover how digital health and diagnostic innovations are creating more accessible, people-centered care.

Dr. Corinna Mann – a specialist in gynecology, endocrinology, and reproductive medicine – unpacks the realities of infertility, age-related success rates across intrauterine insemination (IUI), in vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI), and the impact of truly personalized, empathetic care. We examine access and costs, employer-sponsored benefits, and why updating key regulations is overdue, plus the proactive role of social egg freezing. Tune in for a concise, insight-rich conversation on how personalization, prevention, and policy shape the future of health.